SEARCH

SEARCH BY CITATION

References

  • 1
    Ritchie AWS & DeKernion JB. The natural history and clinical features of renal carcinoma. Semin Nephrol 1987; 7: 131 9
  • 2
    Dal Bianco M, Artibani W, Bassi PF. Prognostic factors in renal cell carcinoma. Eur Urol 1988; 15: 73 6
  • 3
    Thrasher JB & Paulson DF. Prognostic factors in renal cancer. Urol Clin N Am 1993; 20: 247 62
  • 4
    Levin J & Conley CL. Thrombocytosis associated with malignant disease. Arch Intern Med 1964; 114: 497 506
  • 5
    Blay JY, Favrot M, Rossi JF, Wijdenes J. Role of interleukin-6 in paraneoplastic thrombocytosis. Blood 1993; 82: 2261 2
  • 6
    Robson CJ, Churchill BM, Anderson W. The results of radical nephrectomy for renal cell carcinoma. Trans Am Assoc Genitourin Surg 1968; 60: 122 9
  • 7
    Cajulis RS, Katz RL, Dekmezian R, El-Naggar A, Ro JY. Fine needle aspiration biopsy of renal cell carcinoma. Acta Cytol 1993; 37: 367 72
  • 8
    Collett D. Modelling Survival Data in Medical Research. New York: Chapman & Hall, 1994
  • 9
    Wirth MP. Immunotherapy for metastatic renal cell carcinoma. Urol Clin North Am 1993; 20: 283 95
  • 10
    Buzaid AC & Todd MB. Therapeutic options in renal cell carcinoma. Semin Oncol 1989; 16: 12 9
  • 11
    Sawczuk IS. Autolymphocyte therapy in the treatment of metastatic renal cell carcinoma. Urol Clin North Am 1993; 20: 297 301
  • 12
    Yagoda A, Petrylak D, Thompson S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am 1993; 20: 303 21
  • 13
    Bono AV. Steroid hormones and hormonal treatment in renal cell carcinoma. In De KernionJB, Pavone-MacalusoM, eds, Tumors of the Kidney. Baltimore: Williams & Wilkins, 1986: 205 27
  • 14
    Osband ME, Lavin PT, Babayan RK et al. Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal cell carcinoma. Lancet 1990; 335: 994 8
  • 15
    West WH, Tauer KW, Yannelli JR et al. Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987; 316: 893 905
  • 16
    Fossa SD, Kramar A, Droz JP. Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha. Eur J Cancer 1994; 30A: 1310 4
  • 17
    Blay JY, Negrier S, Combaret V et al. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 1992; 52: 3317 22
  • 18
    Strohmeyer T & Ackermann R. Classic and modern prognostic indicators in renal cell carcinoma. Urol Int 1991; 47: 203 12
  • 19
    Maldazys JD & DeKernion JB. Prognostic factors in metastatic renal carcinoma. J Urol 1986; 136: 376 9
  • 20
    Shimazui T, Tomobe M, Hattori K, Uchida K, Akaza H, Koiso K. A prognostic significance of nucleolar organizer region (AgNOR) in renal cell carcinoma. J Urol 1995; 154: 1522 6
  • 21
    Belldegrun A, Franklin JR, Figlin R. Commentary on prognostic factors in renal cell carcinoma. J Urol 1995; 154: 1274
  • 22
    Davis WM & Ross AOM. Thrombocytosis and thrombocythemia: the laboratory and clinical significance of an elevated platelet count. Am J Clin Pathol 1973; 59: 243 7
  • 23
    Silvis SE, Turkbas N, Doscherholmen A. Thrombocytosis in patients with lung cancer. JAMA 1970; 211: 1852 4
  • 24
    Hernandez E, Lavine M, Dunton CJ, Gracely E, Parker J. Poor prognosis associated with thrombocytosis in patients with cervical cancer. Cancer 1992; 69: 2975 7
  • 25
    Burstein SA & Harker LA. Control of platelet production. Clin Haematol 1983; 12: 3 22
  • 26
    Metcalf D, Nicola NA, Gearing DP. Effects of injected leukemia inhibitory factor on hematopoietic and other tissues in mice. Blood 1990; 76: 50 6
  • 27
    Asano S, Okano A, Ozawa K et al. In vivo effects of recombinant human interleukin-6 in primates: simulated production of platelets. Blood 1990; 75: 1602 5
  • 28
    Kimura H, Ishbashi T, Shikama Y et al. Interleukin 1 (IL-1) induces thrombocytosis in mice: possible implication of IL-6. Blood 1990; 76: 2493 500
  • 29
    Hollen CW, Henthorn J, Koziol JA, Burstein SA. Elevated serum interleukin-6 levels in patients with reactive thrombocytosis. Br J Haematol 1991; 79: 286 90
  • 30
    Miki S, Iwano M, Miki Y et al. IL-6 functions as an autocrine growth factor in renal carcinomas. FEBS Lett 1989; 250: 607 10
  • 31
    Takenawa J, Kanako Y, Fukyumoto M et al. Enhanced expression of IL-6 in primary human renal cell carcinoma. J Natl Cancer Inst 1991; 83: 1668 72
  • 32
    Serve H, Steinhauser G, Oberberg B, Flegel WA, Northoff H, Berdell WE. Studies on the interaction between interleukin 6 and human malignant non hematopoietic cell lines. Cancer Res 1991; 51: 3862 6
  • 33
    Smith M, Switalska H, Rothman V. Thrombospondin (TSP) levels in patients with malignancy. Proc Am Soc Clin Oncol 1990; 9: 6
  • 34
    Tuszynski GP, Gasic TB, Rothman VL, Knudsen KA, Gasic GJ. Thrombospondin: a potentiator of tumor cell metastasis. Cancer Res 978; 47: 4130 3
  • 35
    Karpatkin S & Pearlstein E. Role of platelets in tumor cell metastases. Ann Intern Med 1981; 95: 636 41
  • 36
    Gasic CJ, Gasic T, Stewart C. Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci 1968; 612: 46 52